Loading...

CytomX Therapeutics

DB:6C1
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6C1
DB
$452M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
  • CytomX Therapeutics has significant price volatility in the past 3 months.
6C1 Share Price and Events
7 Day Returns
-6.4%
DB:6C1
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-58.3%
DB:6C1
-10.6%
DE Biotechs
-6.2%
DE Market
6C1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CytomX Therapeutics (6C1) -6.4% -6.3% -39.2% -58.3% -30.2% -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 6C1 underperformed the Biotechs industry which returned -10.6% over the past year.
  • 6C1 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
6C1
Industry
5yr Volatility vs Market
Related Companies

6C1 Value

 Is CytomX Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CytomX Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €8.864.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CytomX Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CytomX Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6C1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.03
NasdaqGS:CTMX Share Price ** NasdaqGS (2019-04-18) in USD $9.99
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CytomX Therapeutics.

DB:6C1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CTMX Share Price ÷ EPS (both in USD)

= 9.99 ÷ -2.03

-4.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CytomX Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CytomX Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CytomX Therapeutics's expected growth come at a high price?
Raw Data
DB:6C1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
-12.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CytomX Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CytomX Therapeutics's assets?
Raw Data
DB:6C1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.90
NasdaqGS:CTMX Share Price * NasdaqGS (2019-04-18) in USD $9.99
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:6C1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CTMX Share Price ÷ Book Value per Share (both in USD)

= 9.99 ÷ 2.90

3.44x

* Primary Listing of CytomX Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CytomX Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CytomX Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CytomX Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6C1 Future Performance

 How is CytomX Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-12.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CytomX Therapeutics expected to grow at an attractive rate?
  • Unable to compare CytomX Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare CytomX Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • CytomX Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6C1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6C1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts -12.6%
DB:6C1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 24.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6C1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6C1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 195 -146 5
2022-12-31 109 -165 4
2021-12-31 65 -146 5
2020-12-31 67 -64 -118 8
2019-12-31 60 -53 -98 9
DB:6C1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 60 -76 -85
2018-09-30 75 -25 -52
2018-06-30 87 -25 -39
2018-03-31 74 175 -50
2017-12-31 72 170 -43
2017-09-30 51 150 -58
2017-06-30 30 142 -62
2017-03-31 24 -16 -51
2016-12-31 15 -2 -59
2016-09-30 11 -12 -57
2016-06-30 9 -6 -57
2016-03-31 8 -28 -50

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CytomX Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • CytomX Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6C1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from CytomX Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6C1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.09 4.14 -3.71 5.00
2022-12-31 -2.24 -0.05 -4.57 5.00
2021-12-31 -2.74 -2.08 -4.33 5.00
2020-12-31 -2.43 -1.99 -3.73 8.00
2019-12-31 -2.15 -1.87 -2.92 8.00
DB:6C1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.03
2018-09-30 -1.29
2018-06-30 -1.01
2018-03-31 -1.34
2017-12-31 -1.16
2017-09-30 -1.57
2017-06-30 -1.70
2017-03-31 -1.41
2016-12-31 -1.63
2016-09-30 -1.63
2016-06-30 -2.18
2016-03-31 -2.91

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CytomX Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CytomX Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CytomX Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6C1 Past Performance

  How has CytomX Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CytomX Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CytomX Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CytomX Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CytomX Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CytomX Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CytomX Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6C1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 59.50 -84.60 33.51 103.87
2018-09-30 75.10 -51.75 32.15 96.26
2018-06-30 86.74 -38.57 30.26 97.64
2018-03-31 74.15 -50.34 27.27 100.16
2017-12-31 71.62 -43.10 25.61 92.28
2017-09-30 50.82 -57.75 23.14 86.92
2017-06-30 30.13 -62.17 21.93 71.34
2017-03-31 24.47 -51.13 20.53 55.97
2016-12-31 15.04 -58.90 19.87 54.76
2016-09-30 10.76 -56.91 18.73 48.91
2016-06-30 9.24 -57.08 17.75 44.73
2016-03-31 8.19 -50.47 15.65 37.06
2015-12-31 7.71 -42.08 12.56 28.36
2015-09-30 7.59 -36.02 10.73 23.19
2015-06-30 7.56 -25.95 8.14 17.95
2015-03-31 6.18 -24.46 7.05 16.93
2014-12-31 5.08 -34.88 6.54 28.30
2013-12-31 0.89 -18.89 4.95 10.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CytomX Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CytomX Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CytomX Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CytomX Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CytomX Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6C1 Health

 How is CytomX Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CytomX Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CytomX Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CytomX Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CytomX Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • CytomX Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CytomX Therapeutics Company Filings, last reported 3 months ago.

DB:6C1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 130.88 0.00 436.13
2018-09-30 157.66 0.00 464.56
2018-06-30 41.13 0.00 335.15
2018-03-31 49.65 0.00 361.48
2017-12-31 69.90 0.00 374.11
2017-09-30 45.48 0.00 331.28
2017-06-30 52.24 0.00 335.92
2017-03-31 73.79 0.00 162.52
2016-12-31 78.48 0.00 181.94
2016-09-30 89.42 0.00 178.47
2016-06-30 101.19 0.00 195.80
2016-03-31 112.71 0.00 180.64
2015-12-31 126.07 0.00 186.71
2015-09-30 53.82 0.00 113.69
2015-06-30 63.60 2.29 125.37
2015-03-31 -6.00 4.07 59.47
2014-12-31 -1.65 3.38 64.40
2013-12-31 0.58 5.49 8.70
  • CytomX Therapeutics has no debt.
  • CytomX Therapeutics has no debt compared to 5 years ago when it was 951.2%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CytomX Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • CytomX Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -23.1% each year.
X
Financial health checks
We assess CytomX Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CytomX Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6C1 Dividends

 What is CytomX Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CytomX Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of CytomX Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CytomX Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CytomX Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6C1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6C1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CytomX Therapeutics has not reported any payouts.
  • Unable to verify if CytomX Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CytomX Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CytomX Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of CytomX Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess CytomX Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CytomX Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CytomX Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6C1 Management

 What is the CEO of CytomX Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sean McCarthy
COMPENSATION $3,213,339
AGE 51
TENURE AS CEO 7.7 years
CEO Bio

Dr. Sean A. McCarthy, D.Phil., has been the Chief Executive Officer and President of CytomX Therapeutics, Inc. since August 2011 and has been its Chairman since December 31, 2018. Dr. McCarthy joined the CytomX Therapeutics, LLC on January 5, 2011 as served as its Chief Business Officer since then. Dr. McCarthy has more than 15 years of experience in the biotech industry, including business development, venture capital and program management. Dr. McCarthy served as a Senior Principal and was a Transactional Partner at Pappas Ventures and helped drive investments in therapeutic, medical device and molecular diagnostic companies, including new company formation. Dr. McCarthy joined Pappas Ventures in August 2006. Dr. McCarthy served as the Vice President of Business Development of SGX Pharmaceuticals Inc., (formerly, Structural Genomix Inc.). He served as a Manager of Drug Discovery Programs and an Associate Director of Program Management at Millennium Pharmaceuticals, Inc. Prior to joining SGX, Dr. McCarthy served as a Senior Scientist and Program Director at Millennium Pharmaceuticals, where he managed biotherapeutic assets for it, including an alliance with Eli Lilly and Co. At Millennium, Dr. McCarthy was responsible for research into gene discovery and for management of several drug discovery programs. Prior to joining the Program Management group at Millennium, he managed an interdisciplinary team of scientists that developed novel genomic techniques for the identification of therapeutic proteins in the context of a major alliance with Eli Lilly. He serves as a Director of CytomX Therapeutics, Inc. Dr. McCarthy serves as a Board Observer of Optherion Inc. He served as the Board Observer of LEAD Therapeutics, Inc. and TYRX, Inc. He served as a Board Observer of TyRx Pharma Inc. since 2008. Dr. McCarthy served as a Board Observer at Afferent Pharmaceuticals, Inc. since 2008. He served as a Director of CoLucid Pharmaceuticals Inc. He served as a Director of Genstruct Inc. (now Selventa, Inc.). Dr. McCarthy is the author of 17 peer reviewed scientific publications and an inventor on six issued patents and 23 filed patent applications. Dr. McCarthy was Post-doctoral Research Fellow at DNAX Research Institute, where he analyzed oncogene-related gene expression. He received a D.Phil. in Cancer Biology from St. John's College, University of Oxford; an M.B.A. from UC San Diego Rady School of Management; and a B.Sc. in Biochemistry and Pharmacology from King's College, University of London with first class honors.

CEO Compensation
  • Sean's compensation has increased whilst company is loss making.
  • Sean's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CytomX Therapeutics management team in years:

1.9
Average Tenure
54
Average Age
  • The average tenure for the CytomX Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Sean McCarthy

TITLE
Chairman
COMPENSATION
$3M
AGE
51
TENURE
7.7 yrs

Debanjan Ray

TITLE
CFO & Head of Corporate Development
COMPENSATION
$2M
AGE
39
TENURE
1.9 yrs

Rachel Humphrey

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
57
TENURE
3.7 yrs

Hoyoung Huh

TITLE
Special Advisor to Chief Executive Officer
COMPENSATION
$187K
AGE
49

Mike Kavanaugh

TITLE
Chief Scientific Officer and Head of Research & Non-Clinical Development
COMPENSATION
$1M
AGE
62
TENURE
4.3 yrs

Danielle Olander

TITLE
Senior Vice President of Talent & Administrative Operations
TENURE
1.9 yrs

Christopher Keenan

TITLE
Vice President of Investor Relations & Corporate Communications

Lloyd Rowland

TITLE
Senior VP & General Counsel
AGE
61
TENURE
0.8 yrs

Sridhar Viswanathan

TITLE
Senior Vice President of Process Sciences & Manufacturing Operations
TENURE
1.5 yrs

Alison Joly

TITLE
Senior Vice President of Program & Alliance Management
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the CytomX Therapeutics board of directors in years:

2.8
Average Tenure
67
Average Age
  • The average tenure for the CytomX Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Sean McCarthy

TITLE
Chairman
COMPENSATION
$3M
AGE
51
TENURE
0.3 yrs

Matt Young

TITLE
Lead Independent Director
COMPENSATION
$169K
AGE
49
TENURE
0.3 yrs

Chip Scarlett

TITLE
Director
COMPENSATION
$167K
AGE
67
TENURE
2.8 yrs

Frederick Gluck

TITLE
Co-Founder & Director
COMPENSATION
$162K
AGE
83
TENURE
8.6 yrs

Henry Lowman

TITLE
Member of Scientific Advisory Board
COMPENSATION
$363K
TENURE
4.3 yrs

Charles Craik

TITLE
Member of Scientific Advisory Board

Jim Wells

TITLE
Member of Scientific Advisory Board
AGE
68

Guy Salvesen

TITLE
Member of Scientific Advisory Board

Toni Ribas

TITLE
Member of Scientific Advisory Board

Jeffrey Weber

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by CytomX Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Mar 19 Buy Lloyd Rowland Individual 04. Mar 19 04. Mar 19 9,000 €9.12 €82,120
X
Management checks
We assess CytomX Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CytomX Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6C1 News

Simply Wall St News

6C1 Company Info

Description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Details
Name: CytomX Therapeutics, Inc.
6C1
Exchange: DB
Founded: 2008
$402,060,856
45,261,282
Website: http://www.cytomx.com
Address: CytomX Therapeutics, Inc.
151 Oyster Point Boulevard,
Suite 400,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CTMX Common Stock Nasdaq Global Select US USD 08. Oct 2015
DB 6C1 Common Stock Deutsche Boerse AG DE EUR 08. Oct 2015
Number of employees
Current staff
Staff numbers
138
CytomX Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 22:03
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/19
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.